2019 GRIFOLS’ SOCIO-ECONOMIC IMPACT
We have determined the socio-economic impact of our activity on the economy of the United States, Spain, Germany and Ireland in terms of wealth generation and job creation during 2019.
Grifols has determined the socio-economic impact of its activity on the economy of the United States, Spain, Germany and Ireland in terms of wealth generation and job creation during 2019.

To this end, the input-output analysis is used, a method in which with known inputs (expenditure on suppliers of goods and services, R+D investment, CAPEX, expenditure made by employees based on the wages received, main taxes, dividends to individuals and legal entities and the interest paid to banks) it is possible to obtain the outputs associated with the activities carried out by Grifols.

The Input – Output framework is an accounting statistical instrument in which all the production and distribution operations that take place in an economy in a given period of time are represented.
### MAIN SOCIO-ECONOMIC IMPACTS

<table>
<thead>
<tr>
<th>Total economic impact M€</th>
<th>Impact of economic growth 2019 vs 2018</th>
<th>Total job creation</th>
<th>Job creation growth 2019 vs 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>8,500</td>
<td>+15%</td>
<td>148,000</td>
<td>+15%</td>
</tr>
</tbody>
</table>

- **Grifols’ Direct Economic Impact**: Amounts to EUR 4,400 million. Additionally, Grifols generates an indirect and induced impact of EUR 4,100 million.
- **41% of Grifols’ Impact**: stems from its plasma center network.
- **Grifols Generates**: 148,000 jobs in total, including 125,000 indirect and induced jobs.
- **60% of Jobs**: are linked to Grifols plasma centers.
- **Grifols Generates**: 5.4 jobs for every 1 job it creates.
SOCIO-ECONOMIC IMPACT IN THE UNITED STATES

<table>
<thead>
<tr>
<th>Economic impact</th>
<th>M$</th>
<th>Multiplier effect</th>
<th>Job creation</th>
<th>%</th>
<th>from plasma centers</th>
</tr>
</thead>
<tbody>
<tr>
<td>7,000</td>
<td>52%</td>
<td>x1.9</td>
<td>130,000</td>
<td>66%</td>
<td>x7.4</td>
</tr>
<tr>
<td>+5% vs 2018</td>
<td></td>
<td></td>
<td>+13% vs 2018</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Grifols generates 6.4 jobs in the U.S. economy for every 1 job it creates.
SOCIO-ECONOMIC IMPACT IN SPAIN

<table>
<thead>
<tr>
<th>Economic impact</th>
<th>M€</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1,700</td>
</tr>
<tr>
<td>+17% vs 2018</td>
<td></td>
</tr>
</tbody>
</table>

Multiplier effect

x2.1 of Grifols' operations in the Spanish economy

Job creation

14,000
+10% vs 2018

Multiplier effect

x3.3 Grifols generates 2.3 jobs in the Spanish economy for every 1 job it creates

+8% vs 2018 in direct job creation
SOCIO-ECONOMIC IMPACT IN GERMANY

**Economic impact**

365 M€

**Multiplier effect**

×2.1 of Grifols’ operations in the German economy

**Job creation**

3,400

77% from plasma centers

**Multiplier effect**

×2.5 Grifols generates 1.5 jobs in the German economy for every 1 job it creates
SOCIO-ECONOMIC IMPACT IN IRELAND

Economic impact

\[ 185 \] M€

Multiplier effect

\[ \times 2.2 \] of Grifols’ operations in the Irish economy

Job creation

\[ 850 \] +10% vs 2018

\[ +33\% \] vs 2018 in direct jobs

Multiplier effect

\[ \times 4.0 \] Grifols generates 3.0 jobs in the Irish economy for every 1 job it creates
A BUSINESS MODEL FOCUSED ON SUSTAINABLE VALUE CREATION

GRIFOLS’ VALUE CREATION IS REFLECTED IN ITS FOUR MAIN DIVISIONS AND ITS ONGOING PURSUIT TO OFFER CROSS-CUTTING SERVICES THAT BOLSTER THE ORGANIZATION AND GENERATE NEW OPPORTUNITIES.

FOUR DIVISIONS

**BIOSCIENCE**
- Leaders in the production of plasma-derived medicines
- 78% of revenues

**DIAGNOSTIC**
- Leaders in cutting-edge diagnostic solutions to analyze blood and plasma, including the development and production of reagents and medical devices
- 14% of revenues

**HOSPITAL**
- Pharmaceutical specialty products for hospital use and innovative technology, software and service solutions to optimize hospital pharmacy operations
- 3% of revenues

**BIO SUPPLIES**
- Biological products for non-therapeutic use
- 5% of revenues

**GRIFOLS ENGINEERING**
- Since its origins, Grifols has focused its efforts on in-house engineering as a lever to innovate and continuously improve its industrial productivity. Grifols Engineering is dedicated to designing and constructing specialty machinery, as well as providing specialized engineering solutions to optimize biotech processes and manufacturing systems.

**GRIFOLS TRAVEL AGENCY**
- As an international company with a strong U.S. presence and subsidiaries in 30 countries, Grifols decided to establish its own travel agency – Grifols Viajes – in order to better manage the global mobility of its workforce. Grifols Viajes offers Grifols’ employees the flexibility they need to plan their trips and optimize work-life balance. The agency also coordinates corporate events, conferences and other internal meetings.
GRIFOLS AROUND THE WORLD

Global headquarters
1

Manufacturing plants
15

R+D+i centers
9

Bioscience Division Centers
5

Diagnostic Division Centers
8

Hospital Division Centers
3

Bio Supplies Division Centers
2

U.S. and Canada
3,391 M€
66.5% of revenues

European Union
857 M€
16.8% of revenues

ROW
851 M€
16.7% of revenues
# Breakdown of Grifols’ Socio-Economic Impact by Country

<table>
<thead>
<tr>
<th>Economic impact (Millions of euros)</th>
<th>Spain</th>
<th>Ireland</th>
<th>Germany: Except plasma centers</th>
<th>Germany: plasma centers</th>
<th>Total Germany</th>
<th>% of plasma centers in Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct</td>
<td>810</td>
<td>85</td>
<td>65</td>
<td>109</td>
<td>175</td>
<td>63%</td>
</tr>
<tr>
<td>Indirect</td>
<td>401</td>
<td>44</td>
<td>34</td>
<td>55</td>
<td>90</td>
<td>62%</td>
</tr>
<tr>
<td>Induced</td>
<td>459</td>
<td>56</td>
<td>37</td>
<td>63</td>
<td>100</td>
<td>63%</td>
</tr>
<tr>
<td>Total impact</td>
<td>1,670</td>
<td>185</td>
<td>137</td>
<td>228</td>
<td>364</td>
<td>63%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Impact on the employment (nº people)</th>
<th>Spain</th>
<th>Ireland</th>
<th>Germany: Except plasma centers</th>
<th>Germany: plasma centers</th>
<th>Total Germany</th>
<th>% of plasma centers in Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct</td>
<td>4,134</td>
<td>213</td>
<td>135</td>
<td>1,236</td>
<td>1,371</td>
<td>90%</td>
</tr>
<tr>
<td>Indirect</td>
<td>7,431</td>
<td>487</td>
<td>504</td>
<td>1,112</td>
<td>1,616</td>
<td>69%</td>
</tr>
<tr>
<td>Induced</td>
<td>2,192</td>
<td>137</td>
<td>164</td>
<td>274</td>
<td>438</td>
<td>63%</td>
</tr>
<tr>
<td>Total employment</td>
<td>13,757</td>
<td>847</td>
<td>803</td>
<td>2,622</td>
<td>3,425</td>
<td>77%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Economic impact (Millions of dollars)</th>
<th>U.S.: Except plasma centers</th>
<th>U.S.: plasma centers</th>
<th>Total U.S.</th>
<th>% in plasma centers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct</td>
<td>1,756</td>
<td>1,906</td>
<td>3,662</td>
<td>52%</td>
</tr>
<tr>
<td>Indirect</td>
<td>784</td>
<td>864</td>
<td>1,648</td>
<td>52%</td>
</tr>
<tr>
<td>Induced</td>
<td>760</td>
<td>865</td>
<td>1,626</td>
<td>53%</td>
</tr>
<tr>
<td>Total impact</td>
<td>3,301</td>
<td>3,635</td>
<td>6,936</td>
<td>52%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Impact on the employment (nº people)</th>
<th>U.S.: Except plasma centers</th>
<th>U.S.: plasma centers</th>
<th>Total U.S.</th>
<th>% in plasma centers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct</td>
<td>4,404</td>
<td>13,046</td>
<td>17,450</td>
<td>75%</td>
</tr>
<tr>
<td>Indirect</td>
<td>37,075</td>
<td>68,867</td>
<td>105,942</td>
<td>65%</td>
</tr>
<tr>
<td>Induced</td>
<td>2,956</td>
<td>3,353</td>
<td>6,309</td>
<td>53%</td>
</tr>
<tr>
<td>Total employment</td>
<td>44,435</td>
<td>85,266</td>
<td>129,702</td>
<td>66%</td>
</tr>
</tbody>
</table>